Indivior PLC Ordinary Shares
$ 37.62
0.44%
05 Jun - close price
- Market Cap 4,446,266,000 USD
- Current Price $ 37.62
- High / Low $ 38.52 / 37.51
- Stock P/E 19.29
- Book Value -1.18
- EPS 1.95
- Next Earning Report 2026-07-30
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.23 %
- ROE 0.12 %
- 52 Week High 41.00
- 52 Week Low 13.42
About
Indivior PLC, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders. The company is headquartered in North Chesterfield, Virginia.
Analyst Target Price
$51.50
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-04-30 | 2026-02-26 | 2025-10-30 | 2025-07-31 | 2025-04-24 | 2025-02-20 | 2024-10-24 | 2024-07-25 | 2024-04-25 | 2024-02-22 | 2023-11-09 | 2023-07-27 |
| Reported EPS | 0.96 | 0.82 | 0.72 | 0.51 | 0.41 | 0.3189 | 0.03 | 0.44 | 0.37 | 0.43 | 0.34 | 0.39 |
| Estimated EPS | 0.66 | 0.674 | 0.41 | 0.25 | 0.23 | 0.26 | 0.31 | 0.4 | 0.42 | 0.28 | 0.3 | 0.22 |
| Surprise | 0.3 | 0.146 | 0.31 | 0.26 | 0.18 | 0.0589 | -0.28 | 0.04 | -0.05 | 0.15 | 0.04 | 0.17 |
| Surprise Percentage | 45.4545% | 21.6617% | 75.6098% | 104% | 78.2609% | 22.6538% | -90.3226% | 10% | -11.9048% | 53.5714% | 13.3333% | 77.2727% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-07-30 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | 0.97 |
| Currency | USD |
Previous Dividend Records
| Jan 1970 | Jan 1970 | |
|---|---|---|
| Payment Date | None | None |
| Amount | $0.095 | $0.032 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: INDV
2026-06-05 21:40:17
Indivior PLC's stock (INDV) on Nasdaq traded steadily around USD 15.45 as of June 5, 2026, drawing investor attention to its valuation metrics. The UK-based addiction-treatment specialist's valuation is being assessed in light of its latest earnings and ongoing legal settlements related to opioids. Investors are focusing on metrics like P/E ratio and enterprise-value-to-EBITDA to gauge its market position compared to other specialty pharmaceutical companies.
2026-06-04 02:38:55
This Zacks.com article highlights five top-ranked efficient stocks: Indivior, ReNew Energy, Lifetime Brands, NetScout Systems, and TEEKAY TANK LTD. These companies were selected based on key efficiency metrics like receivables turnover, asset utilization, inventory turnover, and operating margin. The article details how these metrics indicate a company's profit-generating potential and strong price performance, showcasing the impressive earnings surprise of each selected firm.
2026-06-03 13:09:19
Indivior PLC's U.S.-listed shares are trading steadily on Nasdaq as investors weigh ongoing litigation against the company's strong growth in addiction treatment products and broader sector sentiment. The company, which specializes in opioid-use disorder treatments, has consistently beaten earnings estimates, yet faces a class-action lawsuit. Analysts have set an average 12-month target price of around USD 19 for its American Depositary Shares.
2026-06-03 08:42:00
Zacks.com has identified five top-ranked efficient stocks that are outperforming their industry peers based on key metrics. The featured companies are Indivior Pharmaceuticals (INDV), ReNew Energy Global (RNW), Lifetime Brands (LCUT), NetScout Systems (NTCT), and TEEKAY TANK LTD (TNK). These selections are based on efficiency ratios such as Receivables Turnover, Asset Utilization, Inventory Turnover, and Operating Margin, indicating strong profit-generating potential.
2026-05-31 02:09:19
Divisadero Street Capital Management sold 2,263,703 shares of Indivior for an estimated $74.76 million in the first quarter of 2026, representing a significant reduction in their position. This sale is seen as profit-taking after Indivior's stock performance and strong first-quarter revenue growth, with the company raising its 2026 guidance. The ARTICLE highlights Indivior's financial metrics and its role in the opioid addiction treatment market, asking if its growth can sustain its stock's run.
2026-05-31 00:10:04
Divisadero Street Capital Management sold 2,263,703 shares of Indivior for an estimated $74.76 million in the first quarter of 2026, a move seen as profit-taking after the stock's significant run-up. Despite the sale, Indivior's business momentum remains strong, with first-quarter revenue rising 19% and adjusted EBITDA more than doubling, leading to an increased 2026 guidance. Investors are now questioning if the company's growth can continue to justify its massive stock performance.
